Routes and formulations for delivery of antisense oligonucleotides

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 217-236

  Hardee, Gregory E ^a   Tillman, Lloyd G ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872469488     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (60)

1. De Smet, M.D., Meenken, C., and Van Den Horn, G.J., Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflammation, 7(3-4): 189-198, 1999.
2. SantaLucia, J., Jr., A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc. Natl. Acad. Sci. USA, 95: 1460-1465, 1998.
3. Krotz, A.H., Mehta, R.C., and Hardee, G.E., Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention. J. Pharm. Sci., 94: 341-352, 2005.
4. Altmann, K.-H. et al., Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia, 50: 168-176, 1996.
5. Geary, R.S. et al., Pharmacokinetics of a tumor necrosis factor-α phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos., 31(11): 1419-1428, 2003.
6. Sewell, K.L. et al., Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J. Pharmacol.Exp. Ther., 303(3): 1334-1343, 2002.
7. Pardridge, W.M., Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Delivery Rev., 15(1-3): 5-36, 1995.
8. Le Corre, S.M. et al., Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targeting the 5-HT1A receptor. Neurochem. Int., 31(3): 349-362, 1997.
9. Whitesell, L. et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Nat. Acad. Sci USA, 90(10): 4665-4669, 1993.
10. Sommer, W. et al., The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev., 8(2): 75-85, 1998.
11. Mustafa, S.J. and Dar, M.S., Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments. US Patent 5932557, 1999.
12. Yazaki, T. et al., Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol., 50(2): 236-242, 1996.
13. Crooke, S.T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 277(2): 923-937, 1996.
14. Boado, R.J., Tsukamoto, H., and Pardridge, W.M., Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS. J. Pharm. Sci., 87(11): 1308-1315, 1998.
15. Vitravene™ product insert.
16. Voigt, M. et al., Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun., 295: 336-341, 2002.
17. Holbrook, K.A. and Wolf., K., The structure and development of skin, in Dermatology in General Medicine. Fitzpatrick, T.B., Eigen, A.Z., Wolff, K., Freedberg, I.M., and Austen, K.F., eds., McGraw Hill, New York, 97-145, 1993.
18. Lampe, M.A. et al., Human stratum corneum lipids: characterization and regional variations. J. Lipid Res., 24: 120-130, 1983.
19. Lee, Y.M. et al., Effect of benzalkonium chloride on percutaneous absorption of antisense phosphorothioate oligonucleotides. Arch. Phar. Res., 19: 435-440, 1996.
20. Mitragotri, S., Blankschtein, D., and Langer, R., Ultrasound-mediated transdermal protein delivery. Science, 269: 850-853, 1995.
21. Regnier, V., Le Doan, T., and Preat V., Parameters controlling topical delivery of oligonucleotides by electroporation. J. Drug Target., 5: 275-289, 1998.
22. Banga, A.K. and Prausnitz, M.R., Assessing the potential of skin electroporation for the delivery of protein-and gene-based drugs. Trends Biotechnol., 16: 408-412, 1998.
23. Roberts, M.S. and Walker, M., Water. The most natural penetration enhancer, in Pharmaceutical Skin Penetration Enhancers. Hadgraft J., ed., Marcel Dekker, New York, 1995, 1-30.
24. Catz, P. and Friend, D.R., Mechanism of skin penetration enhancer: Ethyl acetate. Pharm. Res., 6: 108, 1988.
25. Millns, J.L. and Maibach, H.I., Mechanisms of sebum production and delivery in man. Arch. Dermatol. Res., 272: 351-362, 1982.
26. Hadgraft, J. and Williams, D.G., Azone. Mechanism of action and clinical effects, in Pharmaceutical Skin Penetration Enhancers. J. Hadgraft, ed., Marcel Dekker, New York, 1993, 175-197.
27. Michniak, B., In-vitro evaluation of a series of azone analogs as dermal penetration enhancers. Int. J. Pharm., 91: 85-93, 1993.
28. Geary, R.S. et al., Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-RAF-1 kinase expression. Drug Metab. Dispos., 25(11): 1272-1281, 1997.
29. Duan, W. et al., Inhaled p38α Mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med., 171(6): 571-578, 2005.
30. Wu-Pong, S. and Byron, P.R., Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Delivery Rev., 19(1): 47-71, 1996.
31. Deshmukh, H., unpublished results, 2002.
32. Yu, J. and Chien, Y.W., Pulmonary drug delivery: physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst., 14(4): 395-453, 1997.
33. Danahay, H. et al., Distribution of a 20-mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to Brown-Norway rats. Pharm. Res., 16(10): 1542-1549, 1999.
34. Templin, M.V. et al., Pharmacokinetic and toxicity profile of a phosphorothioate oligodeoxynucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev., 10: 359-368, 2000.
35. Hung, E., unpublished observations, 2005.
36. Nyce, J.W. and Metzger, W.J., DNA antisense therapy for asthma in an animal model. Nature (London), 385(6618): 721-725, 1997.
37. Nyce, J.W., Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Expert Opin. Invest. Drugs, 6(9): 1149-1156, 1997.
38. Karras, J.G., Geary, R.S., and Gregory, S.A., Inhaled antisense oligonucleotide therapies: inspiration and progress. Drug Discov. Today, in press.
39. Humphrey, M.J., The oral bioavailability of peptides and related drugs, in Delivery Systems for Peptide Drugs. Davis, S.S., Illum, L., and Tomlinson, E., eds., Plenum Press, New York, pp. 139-151, 1986.
40. Agrawal, S. and Zhang, R., Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. Handb. Exp. Pharmacol., 131 (Antisense Research and Application): 525-543, 1998.
41. Nicklin, P.L., Craig, S.J., and Phillips, J.A., Pharmacokinetic properties of phosphorothioates in animals-absorption, distribution, metabolism and elimination. Handb. Exp. Pharmacol., 131(Antisense Research and Application): 141-168, 1998.
42. Zhang, R. et al., In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharmacol., 50(4): 545-556, 1995.
43. Zhang, R. et al., Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotides phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther., 278(2): 971-979, 1996.
44. Altmann, K.-H. et al., Second generation of antisense oligonucleotides. From nuclease resistance to biological efficacy in animals. Chimia, 50(4): 168-176, 1996.
45. Bennett, C.F. et al., Antisense oligonucleotide-based therapeutics, in Gene and Cell Therapy:Therapeutic Mechanisms and Strategies. Templeton, N.S., ed., Marcel Dekker, New York, pp. 347-374, 2004.
46. Kolbe, H.V.J. and Boussif, O., Use of a cationic polymer for the preparation of a complex with nucleic acid and related compositions, European Patent Application, EP 987029, 2000.
47. Richardson, S.C.W., Kolbe, H.V.J., and Duncan, R., Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm., 178(2): 231-243, 1999.
48. Zobel, H.P. et al., Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part 2. Characterization of antisense oligonucleotides loaded copolymer nanoparticles. Eur. J. Pharm. Biopharm., 48(1): 1-12, 1999.
49. Khatsenko, O. et al., Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev, 10(1): 35-44, 2000.
50. Anderberg, E.K., Lindmark, T., and Artursson, P., Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res., 10(6):857-864, 1993.
51. Lane, M.E., O’Driscoll, C.M., and Corrigan, O.I., The relationship between rat intestinal permeability and hydrophilic probe size. Pharm. Res., 13(10): 1554-1558, 1996.
52. Soderholm, J.D. et al., Reversible increase in tight junction permeability to macromolecules in rat ileal mucosa in vitro by sodium caprate, a constituent of milk fat. Dig. Dis. Sci., 43(7): 1547-1552, 1998.
53. Teng, C.-L., unpublished results, 1998.
54. Lee, V.H., Yamamoto, A., and Kompella, U.B., Mucosal penetration enhancers of facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst., 8(2): 91-192, 1991.
55. Hollander, D., The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn’s disease. Scand. J. Gastro., 27: 721-726, 1992.
56. Geary, R.S., unpublished results, 2004.
57. Tillman, L.G., Geary, R.S., and Hardee, G.E., Oral delivery of antisense oligonucleotides: plasma bioavailability of ISIS 104838 in man. Accepted for publication, J. Pharm. Sci., 2007.
58. Hardee, G.E. et al., A Phase I Study of Orally Administered ISIS 301012 for the Reduction of ApoB-100 and LDL-cholesterol. Manuscript in preparation, 2006.
59. Neurath, M.F. et al., Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. (NY), 2(9): 998-1004, 1996.
60. Zhang, R. and Agrawal, S., Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides, PCT Int. Appl., WO 9840058, 1998.